Compositions and methods using stem cells in cutaneous wound healing
AssigneeNeostem, Inc.
InventorVincent Falanga
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds.
Claims42
A fibrin sealant comprising a fibrinogen complex (FC) component, a thrombin component, and a cellular component, wherein concentration of fibrinogen used to form the gel is between from about 2 to about 5 mg/ml, wherein the cellular component comprises one or more of stem/progenitor cells, and wherein the fibrin sealant comprises at least 1.5-2.0×106 stem/progenitor cells/cm2.
A method of using a fibrin sealant, comprising:
- a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant, said fibrin sealant comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is about 25 U/ml, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2;
- b) administering the fibrin sealant to a cutaneous wound, wherein the fibrin sealant is administered in the form of a polymerized gel or spray.
A method of ameliorating the formation of scars at a wound site, comprising:
- a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant, said fibrin sealant comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is about 25 U/ml, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2;
- b) administering the fibrin sealant to a wound site, wherein the fibrin sealant is administered in the form of a polymerized gel or spray.
A method of making a fibrin sealant comprising:
- providing a fibrinogen complex (FC) component, a calcic thrombin component, and a cellular component;
- adding the cellular component to the FC component before admixture of the FC component with the calcic thrombin component;
- and adding the calcic thrombin component to the combined FC/cellular component mixture, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2.
A kit for preparing a fibrin sealant comprising, a) a first vial or first storage container containing a fibrinogen complex component, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and b) a second vial or second storage container having a thrombin component, said kit further containing instructions for use thereof.
A fibrin sealant comprising a fibrinogen complex (FC) component, a thrombin component, and a cellular component, wherein concentration of fibrinogen used to form the gel is between from about 2 to about 5 mg/ml, wherein the cellular component comprises one or more of stem/progenitor cells, and wherein the fibrin sealant comprises at least 1.5-2.0×106 stem/progenitor cells/cm2, wherein the stem/progenitor cells are very small embryonic-like (VSEL) stem cells.
A method of using a fibrin sealant, comprising:
- a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant, said fibrin sealant comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is about 25 U/ml, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2, wherein the stem/progenitor cells are very small embryonic-like (VSEL) stem cells;
- b) administering the fibrin sealant to a cutaneous wound, wherein the fibrin sealant is administered in the form of a polymerized gel or spray.
A method of ameliorating the formation of scars at a wound site, comprising:
- a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant, said fibrin sealant comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is about 25 U/ml, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2, wherein the stem/progenitor cells are very small embryonic-like (VSEL) stem cells;
- b) administering the fibrin sealant to a wound site, wherein the fibrin sealant is administered in the form of a polymerized gel or spray.
A method of making a fibrin sealant comprising:
- providing a fibrinogen complex (FC) component, a calcic thrombin component, and a cellular component;
- adding the cellular component to the FC component before admixture of the FC component with the calcic thrombin component;
- and adding the calcic thrombin component to the combined FC/cellular component mixture, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2, wherein the stem/progenitor cells are very small embryonic-like (VSEL) stem cells.
A method of treating scleroderma comprising:
- a) combining stem/progenitor cells with a fibrin sealant to form a wound sealant, said fibrin sealant comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is about 25 U/ml, wherein the concentration of fibrinogen is from about 2 to about 5 mg/ml, and wherein the final concentration of stem/progenitor cells is at least from about 1.5 to about 2.0×106 stem/progenitor cells/cm2;
- b) administering the fibrin sealant to a scleroderma ulcer, wherein the fibrin sealant is administered in the form of a polymerized gel or spray.
Dependencies are inferred from the claim text.